Get the Stockscreener App
7.27
2.02%
-0.15
Eupraxia Pharmaceuticals Inc stock is traded at $7.27, with a volume of 193.07K.
It is down -2.02% in the last 24 hours and up +1.39% over the past month.
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs. Currently, the company has two distinct clinical development programs, one targeting EoE and the second targeting chronic Osteoarthritis pain in the knee and has completed a Phase 2b clinical trial with EP-104IAR in knee OA.
See More
Previous Close:
$7.42
Open:
$7.715
24h Volume:
193.07K
Relative Volume:
0.87
Market Cap:
$447.13M
Revenue:
-
Net Income/Loss:
$-38.61M
P/E Ratio:
-7.3308
EPS:
-0.9917
Net Cash Flow:
$-29.20M
1W Performance:
+2.25%
1M Performance:
+1.39%
6M Performance:
+28.22%
1Y Performance:
+81.30%
1-Day Range:
$7.05
$7.715
1-Week Range:
$7.05
$8.13
52-Week Range:
$3.6669
$9.32
Eupraxia Pharmaceuticals Inc Stock (EPRX) Company Profile
Name
Eupraxia Pharmaceuticals Inc
Sector
Industry
Phone
-
Address
-
Compare EPRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EPRX
Eupraxia Pharmaceuticals Inc
|
7.27 | 447.13M | 0 | -38.61M | -29.20M | -0.9917 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Eupraxia Pharmaceuticals Inc Stock (EPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-23-26 | Initiated | William Blair | Outperform |
| Jul-24-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-26-25 | Initiated | H.C. Wainwright | Buy |
| Jun-16-25 | Initiated | Canaccord Genuity | Speculative Buy |
| Feb-21-25 | Initiated | Craig Hallum | Buy |
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
View All
Eupraxia Pharmaceuticals Inc Stock (EPRX) Latest News
Eupraxia reports endoscopy score data from EoE trial By Investing.com - Investing.com Australia
Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week - Investing News Network
Eupraxia Pharmaceuticals Highlights Strong EP-104GI EoE Data From RESOLVE Trial at DDW - TipRanks
Why 20 shots matter: Eupraxia links fuller dosing to lower EoE scope scores - Stock Titan
Eupraxia Pharmaceuticals Price Target Maintained With a $11.00/Share by HC Wainwright & Co. - Moomoo
Eupraxia Pharmaceuticals: Tambiah to Succeed Mark Kowalski - Moomoo
Eupraxia Pharmaceuticals Names New Chief Medical Officer to Steer Late-Stage Pipeline - TipRanks
Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer - Investing News Network
Eupraxia appoints Dr. Jeymi Tambiah as chief medical officer - Investing.com UK
Eupraxia appoints Dr. Jeymi Tambiah as chief medical officer By Investing.com - Investing.com Nigeria
Surgeon-scientist Jeymi Tambiah joins Eupraxia as CMO - Stock Titan
Osteoarthritis Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Observe | Merck KGaA, Peptinov, LG Chem, Akan Bioscience, BioTissue,Inc., Eupraxia Pharmaceuticals Inc., OliPass Corp - Barchart.com
A Quick Look at Today's Ratings for Eupraxia Pharmaceuticals(EPRX.US), With a Forecast Between $11 to $16 - Moomoo
Eupraxia Pharmaceuticals (EPRX) to Release Quarterly Earnings on Wednesday - MarketBeat
Eupraxia Pharmaceuticals Shares Drop After $70 Million Offering Pricing - MSN
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Eupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting - Sahm
EPRX Eupraxia Pharmaceuticals posts wider than expected Q4 2025 loss on zero revenue, shares dip nearly 1 percent. - Cổng thông tin điện tử Tỉnh Sơn La
Eupraxia Pharmaceuticals Inc. - Mena FN
Stocks in play: Eupraxia Pharmaceuticals Inc. - Barchart.com
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Receives Buy Rating from HC Wainwright - MarketBeat
Eupraxia Pharmaceuticals to Showcase EP-104GI Data at Digestive Disease Week 2026 - TipRanks
EP-104GI esophagitis data and DDW investor event for Eupraxia (TSX: EPRX) - Stock Titan
Eupraxia Pharmaceuticals Reports Positive Nine-Month Tissue Health and Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis - Investing News Network
Eupraxia Posts Strong 36-Week EoE Data From Highest-Dose Cohort in RESOLVE Trial - TipRanks
Experimental esophagus treatment kept symptoms in remission for 36 weeks - Stock Titan
Canadian Investment Regulatory Organization Trading Halt – EPRX.WT.A - Weekly Voice
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Raised to "Sell" at Wall Street Zen - MarketBeat
Eupraxia Pharmaceuticals (EPRX) Stock: Trendline Structure (Selling Pressure) 2026-04-16Expert Entry Points - Cổng thông tin điện tử tỉnh Lào Cai
Eupraxia Pharmaceuticals to Highlight Drug-Delivery Pipeline at April Investor Conferences - TipRanks
Eupraxia (EPRX) to showcase Diffusphere pipeline at April investor events - Stock Titan
Eupraxia Pharmaceuticals (EPRX) schedules June 18, 2026 annual meeting - Stock Titan
EPRX Price Today: Eupraxia Pharmaceuticals Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Eosinophilic Esophagitis Market in the US to Grow at 13.2% CAGR During the Forecast Period (2026–2036) Owing to the Emergence of Drug Classes Such as TSLP Inhibitors, Glucocorticoid Receptor Agonists, and Immunomodulators | DelveInsight - GlobeNewswire Inc.
Eupraxia Pharmaceuticals to Present at Upcoming Investor Conferences - Investing News Network
Eupraxia's April 21 Toronto conference presentation will be webcast - Stock Titan
Is Eupraxia Pharmaceuticals (EPRX) Stock tied to economic cycles | Price at $7.12, Up 3.72%Trading Ideas - Newser
New Highs: Can VLYPP weather a recessionTrade Performance Summary & AI Driven Price Forecasts - baoquankhu1.vn
Top iBio (IBIO) Competitors 2026 - MarketBeat
Whats the beta of Eupraxia Pharmaceuticals Inc stock2026 Top Gainers & Technical Pattern Recognition Alerts - baoquankhu1.vn
Eupraxia Pharmaceuticals Inc. (EPRX) - Minichart
Institution Moves: What are Eupraxia Pharmaceuticals Incs recent SEC filings showing2026 EndofYear Setup & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
How does Eupraxia Pharmaceuticals (EPRX) Stock compare to competitors | Price at $6.77, Down 4.65%Profit Surge - Newser
Can Eupraxia Pharmaceuticals (EPRX) Stock Go Higher | Price at $7.10, Down 0.98%Shared Trade Ideas - Newser
EPRX SEC FilingsEupraxia Pharmac 10-K, 10-Q, 8-K Forms - Stock Titan
New strong sell stocks for April 2nd - MSN
New Strong Sell Stocks for April 2nd - Yahoo Finance
ETFs Investing in Eupraxia Pharmaceuticals, Inc. Stocks - TradingView
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Short Interest Up 26.3% in March - MarketBeat
Eupraxia Pharmaceuticals Projected to Post Earnings on Tuesday - National Today
Eupraxia Pharmaceuticals Inc Stock (EPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):